- Federal agenciesMay improve coordination of federal research programs on lung cancer in women and underserved groups.
- Targeted stakeholdersCould identify gaps that lead to targeted research on environmental and genomic risk factors.
- Targeted stakeholdersMay inform a national screening strategy to expand access for eligible women and underserved populations.
Women and Lung Cancer Research and Preventive Services Act of 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill requires the HHS Secretary, consulting with the Secretaries of Defense and Veterans Affairs, to conduct an interagency review on the status of lung cancer research in women and underserved populations.
The review must evaluate research gaps, opportunities to accelerate research, access to preventive services, and national education and screening strategies.
It must produce a report for Congress within two years of enactment.
Low-cost, technocratic review with bipartisan potential increases prospects, but passage depends on committee action and floor scheduling.
Relative to its intended legislative type, this bill is a clear, appropriately scoped study/reporting mandate that identifies responsible agencies and specifies the content and timeline for a comprehensive review and a report to Congress. It lacks fiscal direction, detailed implementation mechanics, and safeguards for data and interagency coordination.
Liberal emphasizes equity and follow-up funding for recommendations
Who stands to gain, and who may push back.
- Targeted stakeholdersImposes administrative work and analysis costs on HHS, DoD, and VA without specific funding.
- Targeted stakeholdersA report requirement may not produce concrete policy changes or new programs by itself.
- Federal agenciesMay duplicate existing federal or academic reviews of lung cancer research and disparities.
Why the argument around this bill splits.
Liberal emphasizes equity and follow-up funding for recommendations
Likely broadly supportive.
Sees focused study on lung cancer in women and underserved groups as addressing health equity and research neglect.
Wants review to lead to concrete funding and targeted interventions.
Generally favorable but pragmatic.
Likes evidence-driven review and interagency approach, while wanting clarity on costs, duplication avoidance, and measurable follow-up before endorsing implementation.
Cautiously open but reserved.
Supports medical research and veteran health, yet wary that the review could justify expanded federal programs, mandates, or future spending without demonstrated cost-effectiveness.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Low-cost, technocratic review with bipartisan potential increases prospects, but passage depends on committee action and floor scheduling.
- No explicit funding or cost estimate included
- Committee workload and prioritization timeline
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberal emphasizes equity and follow-up funding for recommendations
Low-cost, technocratic review with bipartisan potential increases prospects, but passage depends on committee action and floor scheduling.
Relative to its intended legislative type, this bill is a clear, appropriately scoped study/reporting mandate that identifies responsible agencies and specifies the content and timeline for a comprehensive review and a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.